Pentti A. Järvinen

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial

Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo‐Repo et al. · The Lancet · 1999 · 865 citations

Rheumatoid Disorder, Rheumatology, Medicine +10

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 359 citations · Full text

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent‐onset rheumatoid arthritis: Five‐year experience from the FIN‐RACo trial

Kari Puolakka, Hannu Kautiainen, Timo Möttönen et al. · Arthritis & Rheumatism · 2005 · 226 citations

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase <scp>III</scp> Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena et al. · Arthritis & Rheumatology · 2018 · 224 citations · Full text

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8